Hypertension:脉压和动脉硬度对心血管疾病的相对作用

2019-01-21 xing.T MedSci原创

由此可见,该研究的结果表明脉压-动脉僵硬度不匹配在社区人群中很常见。CFPWV可能会改变CPP与CVD风险之间的关联,在CPP和CFPWV升高的患者中观察到的风险最大。

脉压经常被用作动脉顺应性的替代标志。然而,脉压与动脉僵硬度不匹配的患病率和预后意义尚不清楚。近日,血管权威杂志Hypertension上发表了一篇研究文章,研究人员测量了Framingham后代队列中2119名参与者(平均年龄为60岁; 57%为女性)的颈动脉-股动脉脉搏波速度(CFPWV)和中心脉压(CPP)。

参与者根据CPP和CFPWV状态分为4组(根据年龄和性别特异性中位数分类为高/低两类)并对血管疾病(CVD)事件进行随访。

在基线时,2119名(39%)参与者中有832人具有不一致的CPP和CFPWV状态,417人具有低CPP和高CFPWV,415人具有高CPP和低CFPWV。CPP-CFPWV不匹配患者CVD事件的多变量调整风险(n=246;中位随访12.6年)(低CPP与高CFPWV的风险比为1.21; 95%CI为0.83-1.76;高CPP与低CFPWV的风险比为0.76; 95%CI为0.49-1.19)与低CPP和低CFPWV患者(参考组)中观察到的CVD风险相当。相反,具有高CFPWV和高CPP(风险比为1.52; 95%CI为1.10-2.11)的参与者经历CVD风险显著增加。CPP和CFPWV状态对CVD风险的相互作用在多变量模型中具有临界意义(P=0.08)。

由此可见,该研究的结果表明脉压-动脉僵硬度不匹配在社区人群中很常见。CFPWV可能会改变CPP与CVD风险之间的关联,在CPP和CFPWV升高的患者中观察到的风险最大。

原始出处:

Teemu J. Niiranen.et al.Relative Contributions of Pulse Pressure and Arterial Stiffness to Cardiovascular Disease The Framingham Heart Study.Hypertension.2019.https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.118.12289

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1727853, encodeId=6f7a1e27853b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 10 00:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800636, encodeId=6ab31800636e5, content=<a href='/topic/show?id=b9d3e2557df' target=_blank style='color:#2F92EE;'>#相对作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72557, encryptionId=b9d3e2557df, topicName=相对作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 15 03:20:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643146, encodeId=a88b164314600, content=<a href='/topic/show?id=928c33288c1' target=_blank style='color:#2F92EE;'>#动脉硬度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33288, encryptionId=928c33288c1, topicName=动脉硬度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=119323130414, createdName=howi, createdTime=Wed Oct 30 21:20:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039016, encodeId=ee83203901681, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Mar 01 15:20:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498531, encodeId=1810149853131, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jan 23 14:20:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501344, encodeId=7fb21501344d6, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Jan 23 14:20:00 CST 2019, time=2019-01-23, status=1, ipAttribution=)]
    2019-08-10 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1727853, encodeId=6f7a1e27853b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 10 00:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800636, encodeId=6ab31800636e5, content=<a href='/topic/show?id=b9d3e2557df' target=_blank style='color:#2F92EE;'>#相对作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72557, encryptionId=b9d3e2557df, topicName=相对作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 15 03:20:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643146, encodeId=a88b164314600, content=<a href='/topic/show?id=928c33288c1' target=_blank style='color:#2F92EE;'>#动脉硬度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33288, encryptionId=928c33288c1, topicName=动脉硬度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=119323130414, createdName=howi, createdTime=Wed Oct 30 21:20:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039016, encodeId=ee83203901681, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Mar 01 15:20:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498531, encodeId=1810149853131, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jan 23 14:20:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501344, encodeId=7fb21501344d6, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Jan 23 14:20:00 CST 2019, time=2019-01-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1727853, encodeId=6f7a1e27853b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 10 00:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800636, encodeId=6ab31800636e5, content=<a href='/topic/show?id=b9d3e2557df' target=_blank style='color:#2F92EE;'>#相对作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72557, encryptionId=b9d3e2557df, topicName=相对作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 15 03:20:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643146, encodeId=a88b164314600, content=<a href='/topic/show?id=928c33288c1' target=_blank style='color:#2F92EE;'>#动脉硬度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33288, encryptionId=928c33288c1, topicName=动脉硬度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=119323130414, createdName=howi, createdTime=Wed Oct 30 21:20:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039016, encodeId=ee83203901681, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Mar 01 15:20:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498531, encodeId=1810149853131, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jan 23 14:20:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501344, encodeId=7fb21501344d6, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Jan 23 14:20:00 CST 2019, time=2019-01-23, status=1, ipAttribution=)]
    2019-10-30 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1727853, encodeId=6f7a1e27853b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 10 00:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800636, encodeId=6ab31800636e5, content=<a href='/topic/show?id=b9d3e2557df' target=_blank style='color:#2F92EE;'>#相对作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72557, encryptionId=b9d3e2557df, topicName=相对作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 15 03:20:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643146, encodeId=a88b164314600, content=<a href='/topic/show?id=928c33288c1' target=_blank style='color:#2F92EE;'>#动脉硬度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33288, encryptionId=928c33288c1, topicName=动脉硬度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=119323130414, createdName=howi, createdTime=Wed Oct 30 21:20:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039016, encodeId=ee83203901681, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Mar 01 15:20:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498531, encodeId=1810149853131, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jan 23 14:20:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501344, encodeId=7fb21501344d6, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Jan 23 14:20:00 CST 2019, time=2019-01-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1727853, encodeId=6f7a1e27853b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 10 00:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800636, encodeId=6ab31800636e5, content=<a href='/topic/show?id=b9d3e2557df' target=_blank style='color:#2F92EE;'>#相对作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72557, encryptionId=b9d3e2557df, topicName=相对作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 15 03:20:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643146, encodeId=a88b164314600, content=<a href='/topic/show?id=928c33288c1' target=_blank style='color:#2F92EE;'>#动脉硬度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33288, encryptionId=928c33288c1, topicName=动脉硬度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=119323130414, createdName=howi, createdTime=Wed Oct 30 21:20:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039016, encodeId=ee83203901681, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Mar 01 15:20:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498531, encodeId=1810149853131, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jan 23 14:20:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501344, encodeId=7fb21501344d6, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Jan 23 14:20:00 CST 2019, time=2019-01-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1727853, encodeId=6f7a1e27853b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 10 00:20:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800636, encodeId=6ab31800636e5, content=<a href='/topic/show?id=b9d3e2557df' target=_blank style='color:#2F92EE;'>#相对作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72557, encryptionId=b9d3e2557df, topicName=相对作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 15 03:20:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643146, encodeId=a88b164314600, content=<a href='/topic/show?id=928c33288c1' target=_blank style='color:#2F92EE;'>#动脉硬度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33288, encryptionId=928c33288c1, topicName=动脉硬度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=119323130414, createdName=howi, createdTime=Wed Oct 30 21:20:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039016, encodeId=ee83203901681, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Mar 01 15:20:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498531, encodeId=1810149853131, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jan 23 14:20:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501344, encodeId=7fb21501344d6, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Jan 23 14:20:00 CST 2019, time=2019-01-23, status=1, ipAttribution=)]

相关资讯

Neurology:研究发现脉压与阿尔茨海默病生物标记物相关

Fig. 脉压与AD生物学标记物(Aβ1-42, P-tau, P-tau/Aβ1-42)的关联性 血压与认知功能降低及阿尔茨海默病痴呆的关系已得到广泛研究,却少有研究探索血压与认知障碍之间的生物学机制。脉压随年龄呈线性升高,可作为血管衰老的指征之一。脉压已被发现可增加阿尔茨海默病性痴呆的发生风险,但这种关联是完全源于其继发的亚临床性脑血管疾病,或是与阿尔茨海默病的病理生理学存在直接关系

Stroke:脉压对急性缺血性卒中患者主要血管事件的预测价值!

由此可见,在缺血性卒中急性期测得的脉压与主要心血管事件和卒中复发的呈非线性J型关系,脉压可能比其他常用的血压参数具有更好的预测能力。

JAHA:急性缺血性卒中后低脉压与不良预后有关!

由此可见,入院时低脉压与AIS患者不良预后相关。

郭艺芳:2015ESC年会4项降压研究简评

2015年欧洲心脏病学会(ESC)年会期间公布了4项降压试验,现就其临床价值简要评论如下。1. PARAMETER研究——梅开二度PARAMETER研究是应用血管紧张素受体脑啡肽酶抑制剂Entresto(即LCZ696)所进行的一项降压试验.去年ESC年会期间所公布的PARADIGM-HF研究发现,与依那普利治疗相比,Entresto可以更为有效的减少慢性心衰患者不良终点事件发生率。基于此研究结果

AHA 2017:环境颗粒物对中国社区人群脉压的影响

在本届美国心脏协会(AHA)2017年科学年会上,来自北京大学第一医院和中国疾病预防控制中心等机构的专家研究团队就环境颗粒物与血压问题发出了响亮的“中国声音”。

JAHA:动脉僵硬度指数和脉压与心血管疾病及死亡的关系!

由此可见,ASI和PP是心血管疾病和死亡结局的独立预测因子。虽然两者都改善了新发疾病的风险预测,但PP似乎比ASI更具有临床价值。